Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

  1. Chappell, K.J.
  2. Mordant, F.L.
  3. Li, Z.
  4. Wijesundara, D.K.
  5. Ellenberg, P.
  6. Lackenby, J.A.
  7. Cheung, S.T.M.
  8. Modhiran, N.
  9. Avumegah, M.S.
  10. Henderson, C.L.
  11. Hoger, K.
  12. Griffin, P.
  13. Bennet, J.
  14. Hensen, L.
  15. Zhang, W.
  16. Nguyen, T.H.O.
  17. Marrero-Hernandez, S.
  18. Selva, K.J.
  19. Chung, A.W.
  20. Tran, M.H.
  21. Tapley, P.
  22. Barnes, J.
  23. Reading, P.C.
  24. Nicholson, S.
  25. Corby, S.
  26. Holgate, T.
  27. Wines, B.D.
  28. Hogarth, P.M.
  29. Kedzierska, K.
  30. Purcell, D.F.J.
  31. Ranasinghe, C.
  32. Subbarao, K.
  33. Watterson, D.
  34. Young, P.R.
  35. Munro, T.P.
  36. Montrer des auteurs +
Revue:
The Lancet Infectious Diseases

ISSN: 1474-4457,  1473-3099

Année de publication: 2021

Volumen: 21

Número: 10

Pages: 1383-1394

Type: Article

DOI: 10.1016/S1473-3099(21)00200-0 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus